Optical molecular imaging and its emerging role in colorectal cancer

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 299, Issue 4, 2010, Pages

  Sheth, Rahul A ^a   Mahmood, Umar ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Animal studies; Cancer genetics; Endoscopy; Fluorescence

Indexed keywords

ALPHA5 INTEGRIN; BETA3 INTEGRIN; BEVACIZUMAB; CATHEPSIN B; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLATE RECEPTOR; FOLINIC ACID; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOCYANINE GREEN; INTERLEUKIN 1BETA CONVERTING ENZYME; IRINOTECAN; LIPOCORTIN 5; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLSERINE; THYMIDYLATE SYNTHASE; TRASTUZUMAB; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; CELL DEATH; CLINICAL EVALUATION; COLON POLYPOSIS; COLORECTAL CANCER; DNA REPAIR; DNA REPLICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; FALSE NEGATIVE RESULT; FLUORESCENCE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTESTINE PREPARATION; LIGHT ABSORPTION; MEDICAL TECHNOLOGY; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NEAR INFRARED SPECTROSCOPY; PATIENT SELECTION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; COLORECTAL NEOPLASMS; DEVICES; PROCEDURES; STAINING;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR IMAGING; STAINING AND LABELING;

EID: 77957345405     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00195.2010     Document Type: Review

References (133)

1. Aisenberg J. Gastrointestinal endoscopy nears "the molecular era". Gastrointest Endosc 68: 528-530, 2008.
2. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096, 2009.
3. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
4. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885-895, 2006.
5. Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, Blankenberg FG, Backer JM. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 13: 504-509, 2007.
6. Barnes KR, Blois J, Smith A, Yuan H, Reynolds F, Weissleder R, Cantley LC, Josephson L. Fate of a bioactive fluorescent wortmannin derivative in cells. Bioconjug Chem 19: 130-137, 2008. (Pubitemid 351213843)
7. Barrett T, Koyama Y, Hama Y, Ravizzini G, Shin IS, Jang BS, Paik CH, Urano Y, Choyke PL, Kobayashi H. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res 13: 6639-6648, 2007. (Pubitemid 350206799)
8. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
9. Bremer C, Ntziachristos V, Weissleder R. Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol 13: 231-243, 2003.
10. Bremer C, Tung C, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7: 743-748, 2001.
11. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005.
12. Bugaj JE, Achilefu S, Dorshow RB, Rajagopalan R. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J Biomed Opt 6: 122-133, 2001.
13. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 49, Suppl 2: 113S-128S, 2008. (Pubitemid 351948040)
14. Cai W, Chen X. Nanoplatforms for targeted molecular imaging in living subjects. Small 3: 1840-1854, 2007.
15. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
16. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 136: 2127-2136.e1, 2009.
17. Chang SK, Rizvi I, Solban N, Hasan T. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin Cancer Res 14: 4146-4153, 2008.
18. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 100: 1704-1719, 2009.
19. Chen J, Tung C, Allport J, Chen S, Weissleder R. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 111: 1800-1805, 2005.
20. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation 105: 2766-2771, 2002. (Pubitemid 34615149)
21. Chen WT, Mahmood U, Weissleder R, Tung CH. Arthritis imaging using a near-infrared fluorescence folate-targeted probe. Arthritis Res Ther 7: R310-R317, 2005.
22. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23: 1803-1810, 2005.
23. Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 90: 1055-1067, 2003. (Pubitemid 37152162)
24. Corsten MF, Hofstra L, Narula J, Reutelingsperger CPM. Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance. Cancer Res 66: 1255-1260, 2006. (Pubitemid 43259900)
25. Demierre MF, Higgins PDR, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 5: 930-942, 2005.
26. Emmert-Buck MR, Roth MJ, Zhuang Z, Campo E, Rozhin J, Sloane BF, Liotta LA, Stetler-Stevenson WG. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 145: 1285-1290, 1994.
27. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. The case for early detection. Nat Rev Cancer 3: 243-252, 2003.
28. Farrugia DC, Ford HER, Cunningham D, Danenberg KD, Danenberg PV, Brabender J, McVicar AD, Aherne GW, Hardcastle A, McCarthy K, Jackman AL. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 9: 792-801, 2003.
29. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
30. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20: 203-213, 2003.
31. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002. (Pubitemid 37328914)
32. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997. (Pubitemid 27076453)
33. Flower RW, Hochheimer BF. Indocyanine green dye fluorescence and infrared absorption choroidal angiography performed simultaneously with fluorescein angiography. Johns Hopkins Med J 138: 33-42, 1976.
34. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
35. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
36. Folli S, Westermann P, Braichotte D, Pèlegrin A, Wagnières G, van den Bergh H, Mach JP. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res 54: 2643-2649, 1994. (Pubitemid 24173752)
37. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 7: 626-634, 2003.
38. Funovics MA, Alencar H, Su HS, Khazaie K, Weissleder R, Mahmood U. Miniaturized multichannel near infrared endoscope for mouse imaging. Mol Imaging 2: 350-357, 2003.
39. Funovics MA, Weissleder R, Mahmood U. Catheter-based in vivo imaging of enzyme activity and gene expression: feasibility study in mice. Radiology 231: 659-666, 2004. (Pubitemid 38668080)
40. Gee MS, Upadhyay R, Bergquist H, Weissleder R, Josephson L, Mahmood U. Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment. Int J Cancer 121: 2492-2500, 2007.
41. Giner JL, Kehbein KA, Cook JA, Smith MC, Vlahos CJ, Badwey JA. Synthesis of fluorescent derivatives of wortmannin and demethoxyviridin as probes for phosphatidylinositol 3-kinase. Bioorg Med Chem Lett 16: 2518-2521, 2006.
42. Goetz M, Kiesslich R. Advances of endomicroscopy for gastrointestinal physiology and diseases. Am J Physiol Gastrointest Liver Physiol 298: G797-G806, 2010.
43. Goetz M, Kiesslich R. Confocal endomicroscopy: in vivo diagnosis of neoplastic lesions of the gastrointestinal tract. Anticancer Res 28: 353-360, 2008.
44. Goetz M, Ziebart A, Foersch S, Vieth M, Waldner M, Delaney P, Galle P, Neurath M, Kiesslich R. In vivo molecular imaging of colorectal cancer with confocal endomicroscopy of epidermal growth factor receptor. Gastroenterology 138: 435-446, 2010.
45. Gross S, Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7: 5-15, 2005.
46. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21, 2001.
47. Gurfinkel M, Thompson AB, Ralston W, Troy TL, Moore AL, Moore TA, Gust JD, Tatman D, Reynolds JS, Muggenburg B, Nikula K, Pandey R, Mayer RH, Hawrysz DJ, Sevick-Muraca EM. Pharma-cokinetics of ICG and HPPH-car for the detection of normal and tumor tissue using fluorescence, near-infrared reflectance imaging: a case study. Photochem Photobiol 72: 94-102, 2000.
48. Hawk E, Viner JL. Statins and cancer - beyond the "one drug, one disease" model. N Engl J Med 352: 2238-2239, 2005.
49. Hazen LG, Bleeker FE, Lauritzen B, Bahns S, Song J, Jonker A, Van Driel BE, Lyon H, Hansen U, Köhler A, Van Noorden CJ. Comparative localization of cathepsin B protein and activity in colorectal cancer. J Histochem Cytochem 48: 1421-1430, 2000.
50. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672-680, 2009.
51. Herschman H. Molecular imaging: looking at problems, seeing solutions. Science 302: 605-608, 2003.
52. Hsiao JK, Law B, Weissleder R, Tung CH. In-vivo imaging of tumor associated urokinase-type plasminogen activator activity. J Biomed Opt 11: 34013, 2006.
53. Hsiung PL, Hsiung PL, Hardy J, Friedland S, Soetikno R, Du CB, Wu AP, Sahbaie P, Crawford JM, Lowe AW, Contag CH, Wang TD. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med 14: 454-458, 2008. (Pubitemid 351499384)
54. Hsu AR, Hou LC, Veeravagu A, Greve JM, Vogel H, Tse V, Chen X. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging 8: 315-323, 2006.
55. Jacoby RF, Seibert K, Cole CE, Kelloff GJ, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60: 5040-5044, 2000.
56. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24: 3245-3251, 2006.
57. Jaffer F, Weissleder R. Molecular imaging in the clinical arena. JAMA 293: 855-862, 2005.
58. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989, 2001.
59. Kaminski MF, Regula J, Kraszewska E, Polkowski M, Wojciechowska U, Didkowska J, Zwierko M, Rupinski M, Nowacki MP, Butruk E. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 362: 1795-1803.
60. Kapitanović S, Radosević S, Kapitanović M, Andelinović S, Ferencić Z, Tavassoli M, Primorać D, Sonicki Z, Spaventi S, Pavelic K, Spaventi R. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112: 1103-1113, 1997. (Pubitemid 27157520)
61. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
62. Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F, Eustace PW, Tobbia I. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 9: 1, 2009.
63. Keller R, Winde G, Terpe HJ, Foerster EC, Domschke W. Fluorescence endoscopy using a fluorescein-labeled monoclonal antibody against carcinoembryonic antigen in patients with colorectal carcinoma and adenoma. Endoscopy 34: 801-807, 2002.
64. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, O'Shaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, Sullivan DC, Woodcock J. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11: 7967-7985, 2005. (Pubitemid 41698738)
65. Kelly K, Alencar H, Funovics M, Mahmood U, Weissleder R. Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide. Cancer Res 64: 6247-6251, 2004.
66. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 96: 327-336, 2005.
67. Kelly KA, Bardeesy N, Anbazhagan R, Gurumurthy S, Berger J, Alencar H, Depinho RA, Mahmood U, Weissleder R. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med 5: e85, 2008.
68. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237, 2007. (Pubitemid 47325606)
69. Kiesslich R, Burg J, Vieth M, Gnaendiger J, Enders M, Delaney P, Polglase A, McLaren W, Janell D, Thomas S, Nafe B, Galle PR, Neurath MF. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 127: 706-713, 2004. (Pubitemid 39208403)
70. Klibanov AL, Martynov AV, Slinkin MA, Sakharov I, Smirnov MD, Muzykantov VR, Danilov SM, Torchilin VP. Blood clearance of radiolabeled antibody: enhancement by lactosamination and treatment with biotin-avidin or anti-mouse IgG antibodies. J Nucl Med 29: 1951-1956, 1988.
71. Laverdière C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100: 3832-3834, 2002.
72. Law B, Curino A, Bugge TH, Weissleder R, Tung CH. Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter. Chem Biol 11: 99-106, 2004.
73. Licha K, Riefke B, Ntziachristos V, Becker A, Chance B, Semmler W. Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization. Photochem Photobiol 72: 392-398, 2000.
74. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
75. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-2621, 2006. (Pubitemid 44511625)
76. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120: 1713-1719, 2001. (Pubitemid 32523489)
77. Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, Shah C, McKinley ET, Xie J, Mutic NJ, Washington MK, LaFleur B, Tantawy MN, Peterson TE, Ansari MS, Baldwin RM, Rothenberg ML, Bornhop DJ, Gore JC, Coffey RJ. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 14: 7413-7422, 2008.
78. Marten K, Bremer C, Khazaie K, Sameni M, Sloane B, Tung CH, Weissleder R. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 122: 406-414, 2002. (Pubitemid 34116992)
79. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, Guo Y, Boorman D, Einspahr J, Alberts DS, Gerner EW. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA 100: 7859-7864, 2003. (Pubitemid 36760060)
80. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17: 545-580, 2003.
81. Mayer RJ. Targeted therapy for advanced colorectal cancer-more is not always better. N Engl J Med 360: 623-625, 2009.
82. Messerli SM, Prabhakar S, Tang Y, Shah K, Cortes ML, Murthy V, Weissleder R, Breakefield XO, Tung CH. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia 6: 95-105, 2004.
83. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005.
84. Montet X, Figueiredo JL, Alencar H, Ntziachristos V, Mahmood U, Weissleder R. Tomographic fluorescence imaging of tumor vascular volume in mice. Radiology 242: 751-758, 2007.
85. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L. Nanoparticle imaging of integrins on tumor cells. Neoplasia 8: 214-222, 2006. (Pubitemid 43671237)
86. Moon WK, Lin Y, O'Loughlin T, Tang Y, Kim DE, Weissleder R, Tung CH. Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate. Bioconjug Chem 14: 539-545, 2003.
87. Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 20: 104-111, 2008. (Pubitemid 350190989)
88. Ntziachristos V. Fluorescence molecular imaging. Annu Rev Biomed Eng 8: 1-33, 2006.
89. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res 69: 1268-1272, 2009.
90. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. Tumor-specific detection of an optically targeted antibody combined with a quencher-conjugated neutravidin "quencher-chaser": a dual "quench and chase" strategy to improve target to nontarget ratios for molecular imaging of cancer. Bioconjug Chem 20: 147-154, 2009.
91. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
92. Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115: 1544-1554, 2009.
93. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20: 84-90, 2009.
94. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, Bogdanov A Jr. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 63: 1936-1942, 2003.
95. Pierce MC, Javier DJ, Richards-Kortum R. Optical contrast agents and imaging systems for detection and diagnosis of cancer. Int J Cancer 123: 1979-1990, 2008.
96. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29, 1999.
97. Psaty BM, Furberg CD. COX-2 inhibitors - lessons in drug safety. N Engl J Med 352: 1133-1135, 2005.
98. Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 355: 950-952, 2006.
99. Rabeneck L, Paszat L. Circumstances in which colonoscopy misses cancer. Frontline Gastroenterol 1: 52-58, 2010.
100. Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 22: 858-865, 2004. (Pubitemid 39665350)
101. Rao J, Dragulescu-Andrasi A, Yao H. Fluorescence imaging in vivo: recent advances. Curr Opin Biotechnol 18: 17-25, 2007. (Pubitemid 46237739)
102. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2: 123-131, 2003. (Pubitemid 37361644)
103. Saltz L. Colorectal cancer treatment: what's next? (or: Is there life after EGFR and VEGF?) Gastrointest Cancer Res 2: S20-S22, 2008.
104. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
105. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345: 144-145; author reply 146, 2001.
106. Schellenberger EA, Bogdanov A, Petrovsky A, Ntziachristos V, Weissleder R, Josephson L. Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy. Neoplasia 5: 187-192, 2003.
107. Schellenberger EA, Weissleder R, Josephson L. Optimal modification of annexin V with fluorescent dyes. Chembiochem 5: 271-274, 2004.
108. Sheth RA, Josephson L, Mahmood U. Evaluation and clinically relevant applications of a fluorescent imaging analog to fluorodeoxyglucose positron emission tomography. J Biomed Opt 14: 064014, 2009.
109. Sheth RA, Upadhyay R, Weissleder R, Mahmood U. Real-time multichannel imaging framework for endoscopy, catheters, and fixed geometry intraoperative systems. Mol Imaging 6: 147-155, 2007.
110. Sinitsyn VV, Mamontova AG, Checkneva YY, Shnyra AA, Domogatsky SP. Rapid blood clearance of biotinylated IgG after infusion of avidin. J Nucl Med 30: 66-69, 1989.
111. Smith A, Blois J, Yuan H, Aikawa E, Ellson C, Figueiredo JL, Weissleder R, Kohler R, Yaffe MB, Cantley LC, Josephson L. The antiproliferative cytostatic effects of a self-activating viridin prodrug. Mol Cancer Ther 8: 1666-1675, 2009.
112. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080, 2005.
113. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res 7: 1118-1126, 2001. (Pubitemid 32708660)
114. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516, 2001.
115. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, Erdkamp FLG, Vos AH, van Groeningen CJ, Sinnige HAM, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JHJM, Dalesio O, Punt CJA. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572, 2009.
116. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997. (Pubitemid 27157312)
117. Upadhyay R, Sheth RA, Weissleder R, Mahmood U. Quantitative real-time catheter-based fluorescence molecular imaging in mice. Radiology 245: 523-531, 2007. (Pubitemid 47612535)
118. Van Gossum A, Munoz-Navas M, Fernandez-Urien I, Carretero C, Gay G, Delvaux M, Lapalus MG, Ponchon T, Neuhaus H, Philipper M, Costamagna G, Riccioni ME, Spada C, Petruzziello L, Fraser C, Postgate A, Fitzpatrick A, Hagenmuller F, Keuchel M, Schoofs N, Deviere J. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 361: 264-270, 2009.
119. Van Rijn J, Reitsma J, Stoker J, Bossuyt P. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 101: 343-350, 2006. (Pubitemid 43381678)
120. Wallace MB, Fockens P. Probe-based confocal laser endomicroscopy. Gastroenterology 136: 1509-1513, 2009.
121. Wallace MB, Keisslich R. Advances in endoscopic imaging of colorectal neoplasia. Gastroenterology 138: 2140-2150, 2010.
122. Walsh JME, Terdiman JP. Colorectal cancer screening: scientific review. JAMA 289: 1288-1296, 2003.
123. Wang TD, Friedland S, Sahbaie P, Soetikno R, Hsiung PL, Liu JTC, Crawford JM, Contag CH. Functional imaging of colonic mucosa with a fibered confocal microscope for real-time in vivo pathology. Clin Gastroenterol Hepatol 5: 1300-1305, 2007.
124. Wang Y, Zhao R, Goldman ID. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem Pharmacol 65: 1163-1170, 2003.
125. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2: 11-18, 2002. (Pubitemid 37328803)
126. Weissleder R, Mahmood U. Molecular imaging. Radiology 219: 316-333, 2001.
127. Weissleder R, Tung CH, Mahmood U, Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 17: 375-378, 1999. (Pubitemid 29166041)
128. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 134: 1296-1310, 2008.
129. Wu Y, Cai W, Chen X. Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging 8: 226-236, 2006. (Pubitemid 44193419)
130. Wunder A, Tung CH, Müller-Ladner U, Weissleder R, Mahmood U. In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum 50: 2459-2465, 2004. (Pubitemid 39062705)
131. Yao VJ, Ozawa MG, Varner AS, Kasman IM, Chanthery YH, Pasqualini R, Arap W, McDonald DM. Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res 66: 2639-2649, 2006.
132. Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H, Cline MJ. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1: 765-767, 1986.
133. Zhang H, Morgan D, Cecil G, Burkholder A, Ramocki N, Scull B, Lund PK. Biochromoendoscopy: molecular imaging with capsule endoscopy for detection of adenomas of the GI tract. Gastrointest Endosc 68: 520-527, 2008.